Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DLM8G6
|
|||
| Drug Name |
Plamotamab
|
|||
| Synonyms |
XmAb 13676
Click to Show/Hide
|
|||
| Drug Type |
Bispecific antibody
|
|||
| Indication | Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 2 | [1] | |
| Company |
Xencor
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | . | [2] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | . | [2] | |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05328102) A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of XmAb13676 (Plamotamab) Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. U.S.National Institutes of Health. | |||
| REF 2 | Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.